Document is current
Any future updates will be listed below
-
Authors
Yoo, Seong-Keun
Fitzgerald, Conall W.
Cho, Byuri Angela
Fitzgerald, Bailey G. https://orcid.org/0000-0002-5566-5953
Han, Catherine
Koh, Elizabeth S.
Pandey, Abhinav
Sfreddo, Hannah
Crowley, Fionnuala
Korostin, Michelle Rudshteyn
Debnath, Neha
Leyfman, Yan https://orcid.org/0000-0002-9331-1857
Valero, Cristina https://orcid.org/0000-0003-3397-2888
Lee, Mark
Vos, Joris L. https://orcid.org/0000-0002-8318-5455
Lee, Andrew Sangho https://orcid.org/0000-0002-2885-6316
Zhao, Karena
Lam, Stanley
Olumuyide, Ezekiel
Kuo, Fengshen https://orcid.org/0000-0003-1797-2896
Wilson, Eric A. https://orcid.org/0000-0002-4104-1445
Hamon, Pauline https://orcid.org/0000-0002-6776-1635
Hennequin, Clotilde
Saffern, Miriam
Vuong, Lynda
Hakimi, A. Ari https://orcid.org/0000-0002-0930-8824
Brown, Brian https://orcid.org/0000-0002-3670-8778
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
Bhardwaj, Nina https://orcid.org/0000-0003-1865-4187
Galsky, Matthew D. https://orcid.org/0000-0001-7655-9378
Schadt, Eric E. https://orcid.org/0000-0002-7892-8808
Samstein, Robert M. https://orcid.org/0000-0001-6860-2401
Marron, Thomas U. https://orcid.org/0000-0001-5903-8191
Gönen, Mithat https://orcid.org/0000-0001-8683-8477
Morris, Luc G. T. https://orcid.org/0000-0002-4417-2280
Chowell, Diego https://orcid.org/0000-0002-1355-5545
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 1 November 2024
First Online: 6 January 2025
Competing interests
: S.-K.Y., B.A.C., C.W.F., C.H., L.G.T.M. and D.C. have a provisional patent application for using routine blood tests and clinical variables to predict cancer immunotherapy response. D.C., R.M.S. and L.G.T.M. are co-inventors on a patent (US11230599/EP4226944A3) filed by MSKCC for using TMB to predict immunotherapy response, licensed to Personal Genome Diagnostics (PGDx). S.-K.Y., C.V., L.G.T.M. and D.C. are co-inventors on a patent (US20240282410A1) filed jointly by Cleveland Clinic and MSKCC for a multi-modal machine learning model to predict immunotherapy response, licensed to Tempus. S.G. reports grants from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, Regeneron and Takeda not related to this study and personal fees from Taiho outside the submitted work. M.D.G reports grants from Bristol Myers Squibb, AstraZeneca, Merck and Genentech, and serves as an advisory board/consultant for Astellas, Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie, Analog Devices, Veracyte, Daiichi and Aktis. E.E.S is an executive officer at Pathos, a clinical-stage oncology drug development and information company, and owns equity in this company. The other authors declare no competing interests.
